US Dividends Aristocrats thread

[Mr. Wood]

3M Board Declares Increase to First Quarter 2021 Dividend
February 2, 2021

dividend on the company's common stock of $1.48 per share for the first quarter of 2021, an increase of 1 percent over the quarterly dividend paid in 2020.

Otter Tail Corporation Increases Quarterly Dividend
February 02, 2021

The increase brings the annual indicated dividend rate to $1.56 per share, an $.08 increase over the 2020 rate

 

[Mr. Wood]

Magellan Midstream Reports Fourth-Quarter 2020 Financial Results
02/02/2021

Annual results

For the year ended Dec. 31, 2020, net income was $817.0 million compared to $1,020.8 million in 2019. The annual decline was driven by decreased contributions from both segments. The refined products segment was negatively impacted by lower demand for refined products due to the ongoing impact of COVID-19 as well as reduced drilling activity in response to the lower commodity price environment and the sale of three marine terminals in early 2020. The crude oil segment generated lower financial results primarily due to less third-party spot shipments, which move at a higher rate than shipments made pursuant to long-term commitments, as a result of unfavorable differentials between the Permian Basin and Houston, as well as lower average tariffs on the Longhorn pipeline resulting from the 2020 expiration of a portion of historical contracts. Further, Magellan earned less from Saddlehorn due to the sale of a 10% interest in early 2020.

Full-year diluted net income per common unit was $3.62 in 2020 and $4.46 in 2019. Annual DCF was $1,044.5 million in 2020, or 1.13 times the amount needed to pay distributions related to 2020, compared to $1,297.5 million in 2019.

As previously announced, Magellan intends to maintain its quarterly cash distribution at the current level of $1.0275 per unit for the remainder of 2021. Based on the current distribution amount and number of units outstanding, distribution coverage for 2021 is expected to be 1.1 times the amount necessary to pay cash distributions for the year, generating excess cash of $100 million for 2021.

Management does not intend to provide specific financial guidance beyond 2021 at this time but expects annual DCF to improve over the next few years. Further, management continues to target distribution coverage of at least 1.2 times once refined products demand and commodity prices return to more historical levels.

one stock which i am keeping in my watchlist becoz it is not as asset heavy as the oil giants.

 

[Mr. Wood]

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
Feb. 3, 2021

- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
- Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis; Adjusted Net Revenues Were $45.784 Billion
- Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2 Percent on a Reported Basis, or 13.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $16.112 Billion, an Increase of 8.4 Percent; Internationally, Humira Net Revenues Were $3.720 Billion, a Decrease of 13.6 Percent on a Reported Basis, or 12.5 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million
- Full-Year Global Net Revenues from the Hematologic Oncology Portfolio Were $6.651 Billion, an Increase of 21.7 Percent on a Reported Basis; Global Imbruvica Net Revenues Were $5.314 Billion, an Increase of 13.7 Percent, with U.S. Net Revenues of $4.305 Billion and International Profit Sharing of $1.009 Billion; Global Venclexta Net Revenues Were $1.337 Billion
- Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion
- Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million

Full-Year 2021 Outlook

AbbVie is issuing its GAAP diluted EPS guidance for the full-year 2021 of $6.69 to $6.89. AbbVie expects to deliver adjusted diluted EPS for the full-year 2021 of $12.32 to $12.52. The company's 2021 adjusted diluted EPS guidance excludes $5.63 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

 

[Mr. Wood]

I noticed the divergence as well. Then again it isn't a perfect correlation so some divergences here and there should be expected.

any insights when will be bear market? or wall street will continue the current bull sh!t, ermm, i mean bull run

 

[Perisher]

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
Feb. 3, 2021

Nice. Vested.

 

[Mr. Wood]

Kraft Heinz Close To Selling Iconic Planters Brand To Hormel For $3B: Report
February 3, 2021

Planters might be best known for its Mr.Peanut mascot and seems like a good match for Hormel Foods, the maker of Skippy peanut butter. The deal also makes sense from a business perspective as Kraft has been divesting brands for years while Hormel has been an active buyer of brands over the years.

If the deal is reached, it would mark Hormel's largest acquisition to date. Sources told WSJ a deal could be confirmed in the coming days, although cautioned there is no guarantee an agreement will be reached.

 

[Mr. Wood]

COVID-19 vaccines to stress-test grocery stores and pharmacies
FEBRUARY 1, 2021

As more Americans become eligible to receive the vaccine, retail chains will assume much of the burden from state health departments, hospitals, and long-term care facilities. Pharmacy industry insiders note the stores are a popular health care access point for many people; already offer immunization services targeting influenza, shingles, and other illnesses; and have the space and manpower to host mass vaccinations.

companies including CVS Health, Walgreens Boots Alliance, Walmart, and Kroger will utilize online scheduling tools that can effectively manage the anticipated crush of appointments.

 

[Mr. Wood]

Dividend Aristocrats In Focus: Cincinnati Financial
Updated on February 3rd, 2021

Based on 2020 earnings-per-share forecasts, Cincinnati Financial stock trades for a price-to-earnings ratio of approximately 30.7. We see fair value at 20 times earnings, meaning it appears shares are quite overvalued at this point.

 

[Mr. Wood]

Dividend Aristocrats In Focus: PPG Industries
Updated on February 3rd, 2021

We are forecasting earnings-per-share of $6.98 for this fiscal year, putting the price-to-earnings ratio at 20.2. That compares unfavorably to our fair value estimate of 17 times earnings, meaning PPG is somewhat overvalued today. As such, we expect a modest ~3% headwind to total returns from valuation in the coming years.

With the stock recently hitting all-time highs, we see patience for investors as key to not chase the stock, and wait for a slightly better price and dividend yield.

 

[Mr. Wood]

Corning Announces Increase in Quarterly Dividend
February 03, 2021

quarterly dividend of $0.24 per common share, a 9% increase versus the company’s previous quarterly common stock dividend of $0.22

We generate strong operating cash flow, and we expect that to continue going forward. We will continue to use our cash to grow, extend our leadership, and reward shareholders. This dividend reflects Corning’s confidence in our future.

 

[Mr. Wood]

Ping An Insurance (Group) Company of China, Ltd.ANNOUNCEMENT OF AUDITED RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
February 3, 2021

Profit grew steadily. In 2020, the Group achieved a 19.5% operating ROE with
operating profit attributable to shareholders of the parent company rising by 4.9% year on year to RMB139,470 million.

Cash dividends continued to increase. Despite the short-term adverse impact on
economic growth, Ping An continued to reward its shareholders. The annual cash
dividend per share for 2020 grew by 7.3% year on year to RMB2.20. The dividend payout ratio based on operating profit attributable to shareholders of the parent company (excluding share repurchases) stood at 28.7%.

dunno iszit local insurers refuse to move forward, many restrictions by MAS, dats why still heavy on insurance and investments.
or iszit dat china company evything oso wanna do evything oso can do.

 

[Mr. Wood]

correction might be over. accumulation in place.

topish

 

[Mr. Wood]

BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance
Feb. 4, 2021

First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
- BD's COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million.
- First fiscal quarter GAAP diluted earnings per share (EPS) increased 285% year-over-year to $3.35.
- Adjusted EPS increased 71.7% year-over-year to $4.55.
- BD is updating its fiscal 2021 guidance, including raising its fiscal 2021 adjusted EPS guidance to $12.75-$12.85.

"While the market continues to be dynamic with the COVID-19 pandemic, BD has emerged as an essential partner to help the world respond to the COVID-19 pandemic from diagnostics to devices used in treatment to injection devices for vaccines and real-time surveillance and reporting.

 

[Mr. Wood]

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
February 4, 2021

Financial Guidance
Bristol Myers Squibb is providing 2021 GAAP EPS guidance in the range of $3.12-$3.32 and is increasing its non-GAAP EPS guidance range from $7.15 - $7.45 to $7.35 - $7.55. Both GAAP and non-GAAP guidance assume current exchange rates. Key 2021 GAAP and non-GAAP line item guidance assumptions are:
• Worldwide revenues increasing in the high-single digits.
• Gross margin as a percentage of revenue to be approximately 80.5%.
• Marketing, selling and administrative expenses to be in-line with 2020 levels for GAAP and increasing in the low-single digit range for non-GAAP.
• Research and development expenses decreasing in the high-single digits for GAAP and
increasing in the mid-single digits for non-GAAP.
• An effective tax rate of approximately 22% for GAAP and approximately 16% for non-GAAP.

Long-term Financial Targets
Bristol Myers Squibb is also affirming 2020-2025 long-term financial targets communicated in January 2021:
• Expects low to mid-single digit revenue CAGR and low double-digit revenue CAGR excluding Revlimid® & Pomalyst® at constant exchange rates
• Expects to maintain low to mid-40s percent non-GAAP operating margin
• Expects significant cash flow generation of $45-$50 billion dollars from 2021 -2023.

 

[Mr. Wood]

Cardinal Health Reports Second-Quarter Results for Fiscal Year 2021
Feb 5, 2021

- Revenue increased 5% to $41.5 billion
- GAAP(1) operating earnings were $461 million, GAAP diluted EPS were $2.13
- Non-GAAP operating earnings decreased 3% to $628 million, non-GAAP diluted EPS increased 14% to $1.74
- Company raised FY21 earnings guidance

Cardinal Health Board of Directors approved a quarterly dividend of $0.4859 per share. The dividend will be payable on April 15, 2021 to shareholders of record at the close of business on April 1, 2021.

The company reached an agreement with the Centers for Disease Control and Prevention (CDC) to act as a network administrator in Phase 2 of the Federal Pharmacy Partnership Strategy for COVID-19. Additionally, the Cardinal Health OptiFreight® Logistics business was selected by the Ohio Department of Health to support efforts to distribute COVID-19 vaccines.

For the 13th consecutive year, Cardinal Health was honored as one of the "Best Places to Work for LGBTQ Equality" by the Human Rights Campaign (HRC) Foundation, achieving 100% on the HRC's 2021 Corporate Equality Index (CEI).

 

[Mr. Wood]

Sanofi delivered close to double-digit Q4 2020 business EPS growth at CER
February 05 2021

Full-year 2020 performance

Sales increased 3.3% to €36,041 million, driven by Dupixent® (€3,534 million, up 73,9%) and Vaccines.
Business EPS of €5.86, up 3.9% on a reported basis and 9.2% at CER ahead of the guidance of 7% to 8%.
In 2020, cost savings of €1,680 million were realized of which approximately 60% were reinvested .
IFRS EPS of €9.82 (up 338.4%), reflecting capital gain from sales of Regeneron.
Entering the sustainable finance landscape with two revolving credit facilities linked to selected sustainability KPIs.
Board meeting held on February 4, proposes annual dividend of €3.20.

2021 financial outlook

Sanofi expects 2021 business EPS to grow high single digit at CER, barring unforeseen major adverse events. Applying average January 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4.5% to -5.5%.

 

[Mr. Wood]

Wynn Resorts, Limited Reports Fourth Quarter and Year End 2020 Results
Feb. 4, 2021

For the year ended December 31, 2020, operating revenues decreased 68.3%, or $4.52 billion, to $2.10 billion, compared to $6.61 billion in the year ended December 31, 2019. Operating revenues decreased $2.04 billion, $1.60 billion, $885.5 million, and $2.3 million at Wynn Palace, Wynn Macau, our Las Vegas Operations, and Encore Boston Harbor, respectively. Encore Boston Harbor opened on June 23, 2019.

Net loss attributable to Wynn Resorts, Limited was $2.07 billion, or $19.37 per diluted share in 2020, compared to net income attributable to Wynn Resorts, Limited of $123.0 million, or $1.15 per diluted share in the year ended December 31, 2019. Our 2020 results included a net tax provision of $564.7 million, primarily related to an increase in the valuation allowance against deferred tax assets no longer expected to be realized. Our 2019 results included a net tax provision of $176.8 million, primarily related to an increase in the valuation allowance on our deferred tax assets. Adjusted net loss attributable to Wynn Resorts, Limited was $2.05 billion, or $19.18 per diluted share, in 2020, compared to adjusted net income of $279.5 million, or $2.61 per diluted share, in the year ended December 31, 2019.

Full year Adjusted Property EBITDA decreased 117.9%, or $2.14 billion, to $(324.3) million, compared to $1.82 billion in the year ended December 31, 2019. Adjusted Property EBITDA decreased $879.2 million, $736.0 million, $470.2 million, and $46.9 million at Wynn Palace, Wynn Macau, our Las Vegas Operations, and Encore Boston Harbor, respectively.

 

[5408854088]

topish

resisting?

 

[Mr. Wood]

Asian Open: Equities finish on a high, dollar bears return
February 8, 2021

With Joe Biden’s $1.9 trillion stimulus package expected to be available by the end of the month, we expect US indices to continue to outperform their European counterparts over the foreseeable future.

 

[Mr. Wood]

resisting?

looks like. especially rsi bear divergence. expecting some more profit taking.
but hope boat can come back